Covigilant Research, LLC Clinical Trials Site Management Organization

Covigilant Research, LLC

Committed To Working Together

Aptose Reports Results for the First Quarter 2022 | Financial Post,

We have ongoing Phase 1 clinical trials for our product candidates HM43239 and Luxeptinib. HM43239 was licensed into Aptose in Q4, …, We have ongoing Phase 1 clinical trials for our product candidates HM43239 and Luxeptinib. HM43239 was licensed into Aptose in Q4, …, Read More

Scroll to Top